4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-100746
Chief Commercial Officer sold 215 shares at $0.69 ($149)
- Chief Commercial Officer acquired 750 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Wiley Matthew T. · Chief Commercial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-09-15 | Exercise or conversion : show line 1 in the form 10b5-1 | +750 | 4,248 | D | ||
| 2024-09-16 | Sale : show line 2 in the form 10b5-1 | −215 | $0.69 | $149 | 4,033 | D |
| Open-market sales · 215 sh · avg $0.69 · $149 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-09-15 | Exercise or conversion : show line 3 in the form 10b5-1 Restricted Stock Units | −750 | 7,500 | D |
Loading xslF345X05/tm2424255-5_4seq1.xml…